Turn Therapeutics (NASDAQ:TTRX) Releases Earnings Results

Turn Therapeutics (NASDAQ:TTRX) released its earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports.

Turn Therapeutics Stock Down 1.1%

Shares of TTRX stock traded down $0.04 on Wednesday, hitting $3.17. 19,970 shares of the stock were exchanged, compared to its average volume of 30,461. The firm has a 50 day moving average price of $3.71. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The company has a market capitalization of $93.19 million and a price-to-earnings ratio of -45.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Hodges Capital Management Inc. bought a new position in shares of Turn Therapeutics in the fourth quarter valued at approximately $39,000. LPL Financial LLC purchased a new stake in shares of Turn Therapeutics in the 4th quarter valued at about $51,000. Jane Street Group LLC purchased a new stake in shares of Turn Therapeutics in the 4th quarter valued at about $68,000. Geode Capital Management LLC bought a new stake in shares of Turn Therapeutics during the 4th quarter valued at about $68,000. Finally, HighTower Advisors LLC purchased a new position in shares of Turn Therapeutics during the fourth quarter worth about $78,000.

Analysts Set New Price Targets

A number of analysts recently commented on TTRX shares. Weiss Ratings assumed coverage on Turn Therapeutics in a report on Monday, January 5th. They set a “sell (e-)” rating on the stock. D. Boral Capital restated a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Turn Therapeutics presently has an average rating of “Hold” and an average price target of $8.00.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.